about
A novel mutation in the pendrin gene associated with Pendred's syndromeTumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects.Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineTreatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study.Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.An update on the pharmacological management of hyperthyroidism due to Graves' disease.Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?Approach to the patient with amiodarone-induced thyrotoxicosis.Diagnosis and treatment of autoimmune hypophysitis: a short review.Amiodarone and the thyroid: a 2012 update.Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-gamma ligands.Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.Growth hormone is necessary for the p53-mediated, obesity-induced insulin resistance in male C57BL/6J x CBA mice.Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge.Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy.Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumors.Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study.Impaired GH secretion to provocative stimuli in two families with hypocalciuric hypercalcaemia.Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists.Improvement of growth hormone deficiency in patients with primary hyperparathyroidism after parathyroidectomy: results of a prospective study.Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH.More on smoking habits and Graves' ophthalmopathy.Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association.Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients.Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study.Serum factors associated with precancerous colonic lesions in acromegaly.Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note.High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.Serum pituitary antibodies in normal pregnancy and in patients with postpartum thyroiditis: a nested case-control study.Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.Primary hyperparathyroidism is associated with marked impairment of GH response to acylated ghrelin.
P50
Q28138680-CC9AA20B-5AD2-4180-A573-09757F798DBCQ33586795-0CE74FA1-B570-4BDD-9BAD-945F2321C9C4Q34128753-14F0A416-F04D-44D5-AB7B-A4F5A8FF2183Q34277844-2F734E39-9D16-4CE1-8684-2778DDA35B22Q34393444-D270D44F-BA8C-4789-A84A-30AC32C92817Q34776728-BC56F0D2-D72F-4740-A552-8BA945AE4D80Q35890596-E324BFBC-F7FF-449D-BB17-1AE829E25A8EQ36161238-EE81A440-D7C4-4845-A190-D410FD134F7DQ37230722-A43E2524-7FED-444A-A547-72873FB22D4AQ37762924-F17D5F5D-B5B3-40F4-AC6C-5E06182A9E92Q37900453-6AF6D6D6-DFA5-4D3E-992F-A67929705206Q37995463-C29C3CB8-4E5D-43FA-B3A6-10B364C2611EQ38117559-F616336D-A19E-4F7C-8174-B25912890E28Q38650974-688A9F5A-28A2-4BB6-B309-11E1687AF17BQ39252361-75FCA9CE-29D7-4123-808A-326FB73D6B75Q40546889-41BDF97F-F304-4315-BE25-A3CD56F13333Q40982205-5963C795-0B05-4EE4-9BB6-33E72DFB7BE3Q41009206-A510DE8F-438C-485E-9522-8BE209C29DC0Q42829933-F806CDB7-EC30-4049-A00C-A21E97D93AD3Q43244160-F7D4AD34-123A-4279-B3B2-393A605FCBC6Q43704338-9CE798D3-0C2F-4787-AC3C-2E00FB977078Q43889388-922F18C0-5DCA-4B1D-9B8F-022FC7FA058DQ44168050-57E8F35C-88B9-45C4-9860-0D572AAA2E85Q44255196-767E2E4C-6FEA-42A7-B012-F789AA785D04Q44418951-50FF4536-5E7E-4A79-8098-694360D0E6B4Q44427429-2D54BCBF-B3AE-4C6C-BFF9-F95A3C04296FQ44655356-283CC0BB-6002-4456-B9B9-73622EC8DF4AQ44661760-CE1415F9-E599-48A8-8A83-818205FEDE9EQ44786966-2DFC77E6-501D-47F1-B340-12E6F6987912Q44878964-A21AA37C-2D74-4CF4-826D-8D5C0E27C74BQ44906164-EA9CF5F9-8B85-4E4B-9D05-19E8A27BEDE7Q45097782-1B595BFD-1CAF-4F0C-8E6D-AE9CCBFEB854Q45393369-8B78D0E2-AC68-44B0-BE29-634CED10EF8DQ45923760-E8061725-C806-4C58-8E22-D10C2D1AFC84Q45965543-8E7EB04D-54A4-4901-B31C-5E3E03911B66Q45976536-A9967FBB-2B89-41A4-BA0E-601878C0D777Q45998725-517B4759-2F41-4DB9-B7B8-81086787B688Q46372817-368E5207-19AF-4F42-B225-DC85806A4DBBQ46457281-10B3F042-C06B-4B6D-9736-7CB526565C57Q46790360-0A2C21A3-001B-4576-837D-6FF569FAB5D8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fausto Bogazzi
@ast
Fausto Bogazzi
@en
Fausto Bogazzi
@es
Fausto Bogazzi
@nl
Fausto Bogazzi
@sl
type
label
Fausto Bogazzi
@ast
Fausto Bogazzi
@en
Fausto Bogazzi
@es
Fausto Bogazzi
@nl
Fausto Bogazzi
@sl
prefLabel
Fausto Bogazzi
@ast
Fausto Bogazzi
@en
Fausto Bogazzi
@es
Fausto Bogazzi
@nl
Fausto Bogazzi
@sl
P106
P21
P31
P496
0000-0001-5975-4411